Virax Biolabs Group Key Executives
This section highlights Virax Biolabs Group's key executives, including their titles and compensation details.
Find Contacts at Virax Biolabs Group
(Showing 0 of )
Virax Biolabs Group Earnings
This section highlights Virax Biolabs Group's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
$1.11
Stock Price
$4.82M
Market Cap
17
Employees
London, None
Location
Financial Statements
Access annual & quarterly financial statements for Virax Biolabs Group, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $156.42K | $8.56K | $- | $123.82K | $99.88K |
| Cost of Revenue | $105.83K | $9.93K | $- | $133.25K | $54.13K |
| Gross Profit | $50.59K | $-1.37K | $- | $-9.43K | $45.75K |
| Gross Profit Ratio | 32.34% | -15.94% | 0.00% | -7.62% | 45.81% |
| Research and Development Expenses | $1.56M | $397.11K | $433.74K | $120.22K | $87.00K |
| General and Administrative Expenses | $4.59M | $5.31M | $1.29M | $457.68K | $602.30K |
| Selling and Marketing Expenses | $- | $26.62K | $13.82K | $57.20K | $7.69K |
| Selling General and Administrative Expenses | $4.59M | $5.33M | $1.30M | $514.88K | $609.99K |
| Other Expenses | $390.36K | $290.47K | $- | $266 | $2.47K |
| Operating Expenses | $6.55M | $5.73M | $1.73M | $635.10K | $696.99K |
| Cost and Expenses | $6.65M | $5.74M | $1.73M | $768.36K | $751.12K |
| Interest Income | $- | $15.47K | $15.44K | $28.64K | $90.69K |
| Interest Expense | $26.88K | $15.47K | $15.44K | $28.64K | $90.69K |
| Depreciation and Amortization | $103.10K | $1 | $1.73M | $644.54K | $651.24K |
| EBITDA | $-6.61M | $-5.44M | $-750 | $- | $-648.77K |
| EBITDA Ratio | -4225.28% | -63570.74% | - | 0.00% | -649.58% |
| Operating Income | $-6.50M | $-5.73M | $-1.73M | $-644.54K | $-651.24K |
| Operating Income Ratio | -4153.25% | -66963.67% | - | -520.55% | -652.05% |
| Total Other Income Expenses Net | $-242.65K | $275.00K | $-16.19K | $-28.38K | $-88.22K |
| Income Before Tax | $-6.74M | $-5.46M | $-1.75M | $-672.91K | $-739.46K |
| Income Before Tax Ratio | -4308.38% | -63751.47% | - | -543.46% | -740.38% |
| Income Tax Expense | $- | $-271 | $-1.77M | $-666.47K | $61.67K |
| Net Income | $-6.73M | $-5.46M | $-1.71M | $-650.98K | $-801.13K |
| Net Income Ratio | -4304.81% | -63748.32% | - | -525.75% | -802.13% |
| EPS | $-3.36 | $-5.13 | $-1.50 | $-0.57 | $-0.70 |
| EPS Diluted | $-3.36 | $-5.13 | $-1.50 | $-0.57 | $-0.70 |
| Weighted Average Shares Outstanding | 2.01M | 1.06M | 1.14M | 1.14M | 1.14M |
| Weighted Average Shares Outstanding Diluted | 2.01M | 1.06M | 1.14M | 1.14M | 1.14M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | March 31, 2024 | September 30, 2023 | March 31, 2023 | September 30, 2022 | March 31, 2022 | September 30, 2021 | March 31, 2021 | September 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.95K | $79.92K | $76.50K | $2.80K | $5.76K | $-92.86K | $- | $109.82K | $14.00K | $24.97K |
| Cost of Revenue | $11.43K | $39.85K | $65.98K | $4.28K | $5.64K | $99.94K | $- | $133.25K | $- | $13.53K |
| Gross Profit | $-6.47K | $40.07K | $10.52K | $-1.48K | $118 | $-192.81K | $- | $-23.43K | $14.00K | $11.44K |
| Gross Profit Ratio | -130.71% | 50.14% | 13.75% | -52.95% | 2.05% | 207.62% | 0.00% | -21.34% | 100.00% | 45.81% |
| Research and Development Expenses | $726.41K | $1.15M | $409.30K | $300.49K | $96.62K | $325.65K | $108.10K | $61.72K | $58.50K | $21.75K |
| General and Administrative Expenses | $2.15M | $2.32M | $2.27M | $4.02M | $1.29M | $831.54K | $454.58K | $172.86K | $284.82K | $152.50K |
| Selling and Marketing Expenses | $- | $33.00K | $33.00K | $25.35K | $51.97K | $9.76K | $4.06K | $15.06K | $42.14K | $1.92K |
| Selling General and Administrative Expenses | $2.15M | $2.29M | $2.31M | $3.99M | $1.34M | $841.29K | $458.64K | $187.92K | $326.96K | $154.42K |
| Other Expenses | $- | $390.36K | $- | $- | $- | $519.23K | $- | $- | $- | $618 |
| Operating Expenses | $2.87M | $3.83M | $2.72M | $4.29M | $1.44M | $1.17M | $566.74K | $249.65K | $385.46K | $176.79K |
| Cost and Expenses | $2.88M | $3.87M | $2.78M | $4.29M | $1.45M | $1.17M | $566.74K | $382.90K | $385.46K | $187.78K |
| Interest Income | $- | $- | $10.11K | $5.86K | $9.61K | $1.29K | $14.14K | $10.51K | $18.13K | $- |
| Interest Expense | $- | $16.76K | $10.11K | $5.86K | $9.61K | $1.29K | $14.14K | $10.51K | $18.13K | $22.67K |
| Depreciation and Amortization | $112.09K | $85.38K | $17.72K | $4.29M | $1.44M | $1.17M | $566.74K | $273.08K | $371.46K | $7.87K |
| EBITDA | $-2.77M | $-3.72M | $-2.69M | $294.07K | $-3.60K | $-1.19M | $5.84K | $260 | $10 | $-154.94K |
| EBITDA Ratio | -55861.18% | -4658.19% | -3514.38% | 10498.75% | -62.50% | 1281.63% | - | 0.24% | 0.07% | -620.52% |
| Operating Income | $-2.88M | $-3.79M | $-2.71M | $-4.29M | $-1.44M | $-1.17M | $-566.74K | $-273.08K | $-371.46K | $-162.81K |
| Operating Income Ratio | -58124.19% | -4742.61% | -3537.54% | -153237.77% | -25010.07% | 1256.60% | - | -248.66% | -2653.29% | -652.05% |
| Total Other Income Expenses Net | $-14.33K | $-34.67K | $-207.98K | $288.21K | $-13.21K | $-7.89K | $-8.30K | $-10.25K | $-18.12K | $-22.05K |
| Income Before Tax | $-2.89M | $-3.82M | $-2.91M | $-4.00M | $-1.45M | $-1.17M | $-575.04K | $-283.33K | $-389.58K | $-184.87K |
| Income Before Tax Ratio | -58413.59% | -4785.99% | -3809.42% | -142948.13% | -25239.34% | 1265.09% | - | -258.00% | -2782.72% | -740.38% |
| Income Tax Expense | $136.66K | $- | $-4.55K | $-4.28M | $-1.45M | $16.65K | $-589.36K | $-248.89K | $-417.58K | $-7.87K |
| Net Income | $-2.76M | $-3.82M | $-2.91M | $-4.01M | $-1.44M | $-1.16M | $-552.42K | $-307.53K | $-343.46K | $-176.99K |
| Net Income Ratio | -55651.67% | -4784.70% | -3803.47% | -143301.79% | -25062.69% | 1245.26% | - | -280.03% | -2453.26% | -708.85% |
| EPS | $-0.89 | $-1.71 | $-1.64 | $-2.58 | $-1.24 | $-1.02 | $-0.49 | $-0.27 | $-0.30 | $-0.02 |
| EPS Diluted | $-0.89 | $-1.71 | $-1.64 | $-2.58 | $-1.24 | $-1.02 | $-0.49 | $-0.27 | $-0.30 | $-0.02 |
| Weighted Average Shares Outstanding | 3.10M | 2.23M | 1.78M | 1.55M | 1.17M | 1.14M | 1.14M | 1.14M | 1.14M | 11.37M |
| Weighted Average Shares Outstanding Diluted | 3.10M | 2.24M | 1.78M | 1.55M | 1.17M | 1.14M | 1.14M | 1.14M | 1.14M | 11.37M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.59M | $9.35M | $21.76K | $17.62K | $22.61K |
| Short Term Investments | $77.32K | $49.26K | $6.00K | $- | $- |
| Cash and Short Term Investments | $3.59M | $9.35M | $21.76K | $17.62K | $22.61K |
| Net Receivables | $217.84K | $- | $- | $928 | $- |
| Inventory | $60.38K | $24.09K | $20.95K | $21.07K | $- |
| Other Current Assets | $512.78K | $281.48K | $6.00K | $- | $- |
| Total Current Assets | $4.38M | $9.63M | $48.71K | $39.62K | $22.61K |
| Property Plant Equipment Net | $1.10M | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $49.77K | $178.40K | $- | $- | $- |
| Goodwill and Intangible Assets | $49.77K | $178.40K | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $54.50K | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $-49.77K | $-178.40K | $- | $- | $- |
| Total Non-Current Assets | $1.10M | $178.40K | $- | $54.50K | $- |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $5.48M | $9.81M | $48.71K | $94.12K | $22.61K |
| Account Payables | $45.63K | $159.91K | $846.47K | $217.15K | $212.84K |
| Short Term Debt | $47.95K | $146.25K | $- | $- | $759.37K |
| Tax Payables | $12.14K | $14.00K | $- | $- | $- |
| Deferred Revenue | $- | $38.25K | $-0 | $- | $-759.37K |
| Other Current Liabilities | $63.12K | $549.99K | $398.94K | $654.29K | $265.53K |
| Total Current Liabilities | $168.85K | $908.40K | $1.25M | $871.43K | $1.24M |
| Long Term Debt | $176.34K | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $176.34K | $- | $- | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $345.19K | $908.40K | $1.25M | $871.43K | $1.24M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.57K | $1.56K | $999 | $265 | $104 |
| Retained Earnings | $-18.53M | $-11.79M | $-6.34M | $-4.63M | $-3.98M |
| Accumulated Other Comprehensive Income Loss | $23.89M | $20.92M | $5.36M | $4.03M | $2.92M |
| Other Total Stockholders Equity | $- | $-0 | $- | $- | $- |
| Total Stockholders Equity | $5.37M | $9.13M | $-974.58K | $-596.18K | $-1.06M |
| Total Equity | $5.14M | $8.90M | $-1.20M | $-777.32K | $-1.22M |
| Total Liabilities and Stockholders Equity | $5.48M | $9.81M | $48.71K | $94.12K | $22.61K |
| Minority Interest | $-227.98K | $-222.40K | $-222.13K | $-181.13K | $-159.03K |
| Total Liabilities and Total Equity | $5.48M | $9.81M | $48.71K | $94.12K | $22.61K |
| Total Investments | $77.32K | $49.26K | $6.00K | $54.50K | $- |
| Total Debt | $224.30K | $146.25K | $3.76K | $179.48K | $759.37K |
| Net Debt | $-3.36M | $-9.21M | $-18.00K | $161.86K | $736.76K |
Balance Sheet Charts
| Breakdown | September 30, 2024 | March 31, 2024 | September 30, 2023 | March 31, 2023 | September 30, 2022 | March 31, 2022 | September 30, 2021 | March 31, 2021 | September 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.29M | $3.59M | $5.11M | $9.35M | $4.57M | $21.76K | $11.68K | $17.62K | $- | $5.65K |
| Short Term Investments | $95.55K | $77.32K | $97.56K | $49.26K | $- | $6.00K | $- | $- | $- | $- |
| Cash and Short Term Investments | $7.38M | $3.59M | $5.11M | $9.35M | $4.57M | $21.76K | $11.68K | $17.62K | $- | $5.65K |
| Net Receivables | $2.36K | $217.84K | $183.36K | $- | $- | $- | $- | $928 | $- | $- |
| Inventory | $261.30K | $60.38K | $24.51K | $24.09K | $- | $20.95K | $21.07K | $21.07K | $- | $- |
| Other Current Assets | $388.14K | $512.78K | $655.42K | $281.48K | $728.56K | $6.00K | $4.38K | $- | $- | $- |
| Total Current Assets | $8.03M | $4.38M | $5.97M | $9.63M | $5.30M | $48.71K | $43.03K | $39.62K | $- | $5.65K |
| Property Plant Equipment Net | $1.36M | $1.10M | $679.42K | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $46.19K | $49.77K | $374.67K | $178.40K | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $46.19K | $49.77K | $374.67K | $178.40K | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $54.50K | $54.50K | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $-49.77K | $-1.05M | $-178.40K | $- | $- | $- | $- | $- | $- |
| Total Non-Current Assets | $1.41M | $1.10M | $1.05M | $178.40K | $- | $- | $54.50K | $54.50K | $- | $- |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $9.44M | $5.48M | $7.03M | $9.81M | $5.30M | $48.71K | $97.53K | $94.12K | $- | $5.65K |
| Account Payables | $118.94K | $45.63K | $408.62K | $159.91K | $427.46K | $846.47K | $236.62K | $217.15K | $- | $53.21K |
| Short Term Debt | $271.10K | $47.95K | $49.68K | $146.25K | $- | $- | $100.00K | $- | $- | $- |
| Tax Payables | $- | $12.14K | $10.41K | $14.00K | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $38.25K | $-0 | $-0 | $- | $- | $- | $- |
| Other Current Liabilities | $303.92K | $63.12K | $318.31K | $549.99K | $715.05K | $398.94K | $709.02K | $654.29K | $- | $256.23K |
| Total Current Liabilities | $693.97K | $168.85K | $787.02K | $908.40K | $1.14M | $1.25M | $1.05M | $871.43K | $- | $309.43K |
| Long Term Debt | $332.10K | $176.34K | $132.03K | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $53.21K |
| Total Non-Current Liabilities | $332.10K | $176.34K | $132.03K | $- | $- | $- | $- | $- | $- | $53.21K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-53.21K |
| Total Liabilities | $1.03M | $345.19K | $919.05K | $908.40K | $1.14M | $1.25M | $1.05M | $871.43K | $- | $309.43K |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $4.34K | $2.57K | $1.81K | $1.56K | $1.17K | $999 | $301 | $265 | $- | $26 |
| Retained Earnings | $-21.28M | $-18.53M | $-14.80M | $-11.79M | $-7.78M | $-6.34M | $-5.18M | $-4.63M | $- | $-994.29K |
| Accumulated Other Comprehensive Income Loss | $29.93M | $23.89M | $21.13M | $20.92M | $12.17M | $5.36M | $4.44M | $4.03M | $- | $- |
| Other Total Stockholders Equity | $-1 | $- | $- | $-0 | $- | $- | $-54.50K | $- | $- | $690.48K |
| Total Stockholders Equity | $8.64M | $5.37M | $6.33M | $9.13M | $4.39M | $-974.58K | $-744.37K | $-596.18K | $- | $-303.78K |
| Total Equity | $8.42M | $5.14M | $6.11M | $8.90M | $4.16M | $-1.20M | $-948.11K | $-777.32K | $- | $-303.78K |
| Total Liabilities and Stockholders Equity | $9.44M | $5.48M | $7.03M | $9.81M | $5.30M | $48.71K | $97.53K | $94.12K | $- | $5.65K |
| Minority Interest | $-228.12K | $-227.98K | $-226.95K | $-222.40K | $-236.76K | $-222.13K | $-203.74K | $-181.13K | $- | $- |
| Total Liabilities and Total Equity | $9.44M | $5.48M | $7.03M | $9.81M | $5.30M | $48.71K | $97.53K | $94.12K | $- | $5.65K |
| Total Investments | $95.55K | $77.32K | $97.56K | $49.26K | $- | $6.00K | $54.50K | $54.50K | $- | $- |
| Total Debt | $603.20K | $224.30K | $181.71K | $146.25K | $3.76K | $3.76K | $179.48K | $179.48K | $- | $- |
| Net Debt | $-6.68M | $-3.36M | $-4.93M | $-9.21M | $-4.57M | $-18.00K | $167.80K | $161.86K | $- | $-5.65K |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-6.74M | $-5.46M | $-1.71M | $-650.98K | $-739.46K |
| Depreciation and Amortization | $103.10K | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.01M | $1.73M | $290.36K | $- | $- |
| Change in Working Capital | $-1.12M | $-216.28K | $644.39K | $59.61K | $-96.82K |
| Accounts Receivables | $-217.84K | $- | $928 | $-928 | $- |
| Inventory | $-60.38K | $20.95K | $121 | $-21.07K | $- |
| Accounts Payables | $-572.25K | $33.94K | $641.16K | $81.61K | $-96.82K |
| Other Working Capital | $-269.56K | $-237.23K | $2.18K | $0 | $- |
| Other Non Cash Items | $497.06K | $-260.60K | $-32.07K | $1.19K | $91.67K |
| Net Cash Provided by Operating Activities | $-6.25M | $-4.18M | $-809.07K | $-590.19K | $-744.61K |
| Investments in Property Plant and Equipment | $-952.50K | $-178.40K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-211.95K | $-178.40K | $- | $- | $- |
| Net Cash Used for Investing Activities | $-1.16M | $-178.40K | $- | $- | $- |
| Debt Repayment | $-206.27K | $146.25K | $100.00K | $- | $- |
| Common Stock Issued | $234 | $13.65M | $519.61K | $403.22K | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.85M | $-111.64K | $193.59K | $585.20K | $704.64K |
| Net Cash Used Provided by Financing Activities | $1.65M | $13.69M | $813.21K | $585.20K | $704.64K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-5.76M | $9.33M | $4.13K | $-4.99K | $-39.97K |
| Cash at End of Period | $3.59M | $9.35M | $21.76K | $17.62K | $22.61K |
| Cash at Beginning of Period | $9.35M | $21.76K | $17.62K | $22.61K | $62.58K |
| Operating Cash Flow | $-6.25M | $-4.18M | $-809.07K | $-590.19K | $-744.61K |
| Capital Expenditure | $-1.16M | $-178.40K | $- | $- | $- |
| Free Cash Flow | $-7.41M | $-4.36M | $-809.07K | $-590.19K | $-744.61K |
Cash Flow Charts
| Breakdown | September 30, 2024 | March 31, 2024 | September 30, 2023 | March 31, 2023 | September 30, 2022 | March 31, 2022 | September 30, 2021 | March 31, 2021 | September 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.76M | $-3.82M | $-2.91M | $-4.01M | $-1.44M | $-1.16M | $-552.42K | $-307.53K | $-343.46K | $-184.87K |
| Depreciation and Amortization | $158.19K | $85.38K | $17.72K | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $-378.84K | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $38.98K | $925.70K | $86.27K | $1.51M | $248.98K | $290.36K | $287.44K | $- | $- | $- |
| Change in Working Capital | $266.39K | $82.23K | $-585.82K | $875.42K | $-1.09M | $644.38K | $12 | $86.22K | $-26.60K | $-24.20K |
| Accounts Receivables | $-2.36K | $-34.48K | $-183.36K | $- | $- | $1.62K | $928 | $7.91K | $-8.84K | $- |
| Inventory | $-64.87K | $-35.88K | $-24.51K | $- | $20.95K | $121 | $-0 | $67.91K | $-88.98K | $- |
| Accounts Payables | $- | $-522.99K | $-49.26K | $390.08K | $-390.08K | $631.79K | $9.36K | $10.40K | $71.21K | $- |
| Other Working Capital | $333.63K | $675.58K | $-328.69K | $485.33K | $-722.56K | $12.46K | $-10.28K | $2 | $0 | $- |
| Other Non Cash Items | $374.24K | $-58.79K | $312.65K | $865.12K | $607.93K | $-650.26K | $263.43K | $-35.63K | $-22.79K | $22.92K |
| Net Cash Provided by Operating Activities | $-1.92M | $-2.79M | $-3.46M | $-1.88M | $-2.30M | $-530.38K | $-278.68K | $-170.73K | $-419.46K | $-186.15K |
| Investments in Property Plant and Equipment | $-248.00K | $-459.92K | $-708.18K | $-178.40K | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $3.65K | $-215.60K | $-178.40K | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-248.00K | $-456.27K | $-708.18K | $-178.40K | $- | $-24.66K | $- | $- | $- | $-245 |
| Debt Repayment | $-51.55K | $-3.66K | $-146.25K | $146.25K | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $234 | $7.10M | $6.56M | $419.61K | $100.00K | $50.00K | $353.22K | $- |
| Common Stock Repurchased | $- | $-85.50K | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.91M | $1.82M | $67.44K | $-398.95K | $6.84M | $120.85K | $272.74K | $123.23K | $461.97K | $176.16K |
| Net Cash Used Provided by Financing Activities | $5.86M | $1.73M | $-78.81K | $6.84M | $6.84M | $540.47K | $272.74K | $123.23K | $461.97K | $176.16K |
| Effect of Forex Changes on Cash | $- | $- | $9.35M | $-9.35M | $- | $2.90K | $- | $- | $- | $245 |
| Net Change in Cash | $7.29M | $-1.52M | $-4.24M | $4.78M | $4.55M | $10.08K | $-5.95K | $-47.50K | $42.51K | $-9.99K |
| Cash at End of Period | $7.29M | $3.59M | $5.11M | $9.35M | $4.57M | $21.76K | $11.68K | $17.62K | $65.12K | $5.65K |
| Cash at Beginning of Period | $- | $5.11M | $9.35M | $4.57M | $21.76K | $11.68K | $17.62K | $65.12K | $22.61K | $15.64K |
| Operating Cash Flow | $-1.92M | $-2.79M | $-3.46M | $-1.88M | $-2.30M | $-530.38K | $-278.68K | $-170.73K | $-419.46K | $-186.15K |
| Capital Expenditure | $-248.00K | $-459.92K | $-708.18K | $-178.40K | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-2.17M | $-3.25M | $-4.17M | $-2.06M | $-2.30M | $-530.38K | $-278.68K | $-170.73K | $-419.46K | $-186.15K |
Virax Biolabs Group Dividends
Explore Virax Biolabs Group's dividend history, including dividend yield, payout ratio, and historical payments.
Virax Biolabs Group News
Read the latest news about Virax Biolabs Group, including recent articles, headlines, and updates.
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
LONDON , March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179). Conducted in collaboration with the United Kingdom's National Health Service, investigators aim to assess the ViraxImmune™ FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients, including those with long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
LONDON , March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion.
Virax Biolabs to Present at 19th World Immune Regulation Meeting
LONDON , March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland. Presentation Details: Title: Evaluation of T cell dysfunction in post acute infection syndromes Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs Date: Wednesday, March 12, 2025, at 20:00 Location: Foyer A1, The Congress Center, Davos, Switzerland Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination LONDON , Feb. 25, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions.
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a supplemental exclusive distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across all remaining Gulf Cooperation Council (GCC) countries, including Saudi Arabia, the United Arab Emirates (UAE), Qatar, and Kuwait. The previous exclusive distribution agreement, announced on January 13, 2025, was limited to Oman and Bahrain.
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries. Specifically, Cosmos Health gains exclusive rights to distribute these kits in Greece and Cyprus, as well as non-exclusive rights in select European countries, including France, Portugal, Spain, The Netherlands, Belgium, Sweden, Finland, Denmark, Norway, Germany, Switzerland, and Austria.
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON , Dec. 17, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders outlining the Company's plans for 2025 and highlights recent accomplishments.
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland
LONDON , Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland. "We are honored to announce this agreement with Tebubio, who will prove to be instrumental in increasing the accessibility of ImmuneSelect for life science institutions across a crucial market such as Europe," said James Foster, CEO of Virax Biolabs.
Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland
LONDON , Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe," said James Foster, CEO of Virax Biolabs.
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (NASDAQ: VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as well as for non-exclusive distribution throughout Europe.
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
LONDON , Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) ("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council ("GCC").
Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference
LONDON , Sept. 9, 2024 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that Chief Operating Officer, Dr Nigel McCracken is presenting at H.C.
Virax Biolabs to Participate at 7th European Congress of Immunology
LONDON , Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland. The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know
Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations.
Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East
LONDON , Aug. 28, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in 13 European countries as well as members of the Gulf Cooperation Council ("GCC") including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom.
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
LONDON , Aug. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares
LONDON , Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about August 23, 2024, subject to the satisfaction of customary closing conditions.
Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today, pursuant to its agreement with Virax Biolabs (NASDAQ: VRAX), that it continues to hold the rights to distribute mpox virus real-time PCR detection kits, with exclusive distribution rights in Greece and Cyprus, and non-exclusive distribution rights across Europe. On August 14, 2024, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations.
Why Is Virax Biolabs (VRAX) Stock Up 115% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is rocketing higher on Thursday morning alongside heavy pre-market trading of the biotechnology company's shares. The heavy trading of Virax Biolabs stock has more than 15.2 million shares trading hands as of this writing.
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
LONDON , April 25, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmune™ T-Cell diagnostic platform for research-use-only ("RUO"), at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress, which is taking place from April 27th to April 30th, 2024, in Barcelona, Spain. The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
Virax Biolabs to Participate at ESCMID Global 2024
LONDON , April 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) on April 27-30, 2024, in Barcelona, Spain. The Company will be showcasing its portfolio of products for research use at Booth F43, and management will be available for discussions with research organizations and potential customers.
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
LONDON , March 15, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
LONDON , Dec. 21, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust, who have a track record in working together to deliver translational immunology research for respiratory viral infections. This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
LONDON , Dec. 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the annual general meetings of the shareholders held on Wednesday, December 6, 2023, at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, approved the proposed 1-for-10 share consolidation of its ordinary shares of US$0.0001 par value each (the "Share Consolidation"). Beginning with the opening of trading on December 18, 2023, the Company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "VRAX", but under a new CUSIP number of G9495L125.
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
LONDON , Sept. 12, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of an early access program for the research-use-only ("RUO") of its proprietary SARS-Cov-2 ViraxImmune T-cell-based test.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for VRAX.